Growth potential Target mid-market hospitals and regional health systems that rely on StageZero’s blood-based cancer detection offerings and expanding CO C protocol services, leveraging their recent product updates and international program launches to upsell integrated testing and digital health platform solutions.

Strategic partnerships Leverage StageZero’s role as a national clinical reference lab to position partnerships with academic medical centers, oncology clinics, and community hospital networks seeking advanced molecular diagnostics, personalized testing menus, and early cancer detection programs.

Digital health edge Highlight the interactive digital health platform and biomarker testing capabilities as differentiators to enterprise customers pursuing value-based care, enabling streamlined reporting, patient engagement, and improved outcomes in oncology pathways.

Financial viability Approach financially mature buyers by citing StageZero’s revenue range and recent financing activity to demonstrate growth trajectory and sustainability, while proposing scalable testing bundles and phased expansion to win contracts with moderate capex requirements.

Geographic expansion Pitch expansion opportunities in markets where StageZero has launched or plans to launch programs such as AVRT in the UK and COC updates in oncology care, aligning sales targets with international and cross-border testing opportunities.